None
Conditions
Interventions
Remimazolam blood concentration and dosage measurement experiment Morning group:None
Remimazolam blood concentration and dosage measurement experiment Afternoon group:None
Remimazolam metabolic enzyme CES1 activity measurement experiment morning group:None
Remimazolam metabolizing enzyme CES1 activity measurement experiment afternoon group:None
Sponsors
Department of Anesthesiology, the Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1:Experiment 1: Measurement Experiment of Remimazolam Blood Concentration and Dosage (1) Age 18-65 years old, ASAI-II class, BMI18.5-25kg/m^2; (2) Inpatients undergoing laparoscopic cholecystectomy; (3) The estimated time of operation is 1.5~2.5 hours; (4) Voluntary participation and signed informed consent. 2: Experiment 2: Remimazolam metabolic enzyme CES1 activity measurement experiment (1) Age 18-75 years old, ASAI-III class; (2) Inpatients undergoing laparoscopic partial hepatic resection; (3) Voluntary participation and signed informed consent.
Exclusion criteria
Exclusion criteria: 1:Experiment 1:Measurement Experiment of Remimazolam Blood Concentration and Dosage(1) Pregnant or lactating women; (2) Patients who are allergic to remazolam or contraindicated; (3) Patients who are dependent on or tolerant to opioids or have long-term alcoholism; (4) Serious cardiovascular system, respiratory system, liver and kidney diseases; (5) History of obstructive sleep apnea; (6) Mental disorders or neurological diseases; (7) Patients who participated in clinical trials of other drugs within the last 3 months; (8) The attending physician or researcher considers that there are other circumstances that are not suitable for participation in this study;(9) Refuse to participate in the study 2: Experiment 2: Remimazolam metabolic enzyme CES1 activity measurement experiment (1) Pregnant or lactating women; (2) Patients who are allergic to remazolam or contraindicated; (3) Patients who are dependent on or tolerant to opioids or have long-term alcoholism; (4) Serious cardiovascular system, respiratory system; (5) History of obstructive sleep apnea; (6) Mental disorders or neurological diseases; (7) Patients who participated in clinical trials of other drugs within the last 3 months; (8) The attending physician or researcher considers that there are other circumstances that are not suitable for participation in this study;(9) Refuse to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remimazolam blood concentration;Remimazolam dosage;CES1 activity; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time when eyelash reflex disappears;Concentration of CNS7054;Intraoperative adverse events;Eye-opening time;Extubation time;Time out of the operating room;Ramsay Sedation score;Drug-related adverse reactions;QoR-15 score; | — |
Countries
China
Contacts
Public ContactChen Jie
Department of Anesthesiology, the Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed